In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Anterolateral papillary muscle rupture with non obstructive coronary artery disease

Session Poster Session 4

Speaker Borges Sara

Congress : Heart Failure 2019

  • Topic : valvular, myocardial, pericardial, pulmonary, congenital heart disease
  • Sub-topic : Valvular Heart Disease - Epidemiology, Prognosis, Outcome
  • Session type : Poster Session
  • FP Number : P2229

Authors : S Borges (Vila Real,PT), F Goncalves (Vila Real,PT), JP Guimaraes (Vila Real,PT), JJ Monteiro (Vila Real,PT), C Ferreira (Vila Real,PT), JI Moreira (Vila Real,PT)

S Borges1 , F Goncalves1 , JP Guimaraes1 , JJ Monteiro1 , C Ferreira1 , JI Moreira1 , 1Hospital Center of Tras-os-Montes and Alto Douro, Cardiology - Vila Real - Portugal ,


BACKGROUND Papillary muscle rupture is an uncommon, potentially fatal condition that frequently results in acute severe mitral regurgitation (MR) and life-threatening cardiogenic shock. Survival depends on prompt recognition and surgical intervention.

CASE PRESENTATION A previously asymptomatic 62-years-old man with unremarkable past medical history, presented to the prehospital emergency team with acute pulmonary edema, without chest pain, less than 30 minutes long; Rapid evolution in cardiac arrest in pulseless electrical activity with return of spontaneous circulation within 6 minutes of cardiopulmonary resuscitation; Transported to the emergency room intubated with orotracheal tube, PaO2/FiO2 ratio <50, BP 86/55 mmHg. Initial
EKG showed supraventricular tachycardia with inverted T wave V4-V6; Laboratory tests revealed Urea/Creatinine 137/5.6 mg/dL, CK 317U/L, T troponin 0.272 ng/mL. Transthoracic echocardiogram showed severe mitral regurgitation (MR) due to possible flail leaflet and hyperdinamic left ventricle (LV). To better characterize the MR mechanism, it was performed a transesophageal echocardiogram that revealed papillary muscle rupture and already moderate LV systolic dysfunction, without any mass/vegetation/thrombus; After insertion of an intra-aortic balloon pump, the patient underwent emergent coronary angiography that showed nonobstructive coronary artery disease and was immediately transferred to a cardiothoracic department. Admitted for emergency surgery less than six hours after the onset of symptoms. At surgical inspection, it was observed rupture of the anterolateral papillary muscle (APM). The patient underwent mitral valve replacement with biologic valve;
Pathology demonstrated acute ischemia of the underlying myocardium. The postoperative period was complicated by the need of inotropic support, prolonged mechanical ventilation and nosocomial pneumonia. Postoperative echocardiography showed no MR. The patient was discharged 29 days later to a medical recovery unit and he is now back to his normal life, without major limitations.

DISCUSSION We have described an unusual presentation of acute MR due to isolated APM rupture in the absence of obstructive artery disease. The papillary muscles are subendocardial structures, and even a small area of myocardial infarction can cause papillary muscle ruptures. Therefore, we cannot exclude the possibility of spontaneous reperfusion, coronary spasm or embolic phenomenon as possible diagnosis hypotheses.

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are